FDA Grants Priority Review For Pfizer COVID-19 Vaccine

(Washington, DC) -- The FDA is granting Pfizer priority review for full approval of its coronavirus vaccine.  

The vaccine is currently approved under an emergency use authorization for people 12 and older.  

Experts say full approval of the Pfizer vaccine could help strengthen the U.S. vaccination effort.  

The priority review shortens the approval process from ten months to six months, with a goal decision date expected in January 2022.